SFRP1 and diffuse idiopathic skeletal hyperostosis: Because SOST and SFRP-1 both act as extracellular antagonists of the Wnt/β-catenin signaling pathway, we suggest that SOST and SFRP-1 play similar roles in patients with DISH.